Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830055/S372

ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, ATTUNE Revision R

Depuy, Inc. · Decision date Sep 9, 2026

MEDTECHLEDGER EXPLANATIONP830055/S372

What did the FDA decide?

FDA recorded decision OK30 on 2026-09-09 for P830055/S372, a 30-day notice under the supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The stated change is the addition of an ingos sub-tier supplier that provides titanium powder used in 3D printing processes for some components of the ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System and ATTUNE Revision Rotating Platform (RP) Knee System. The applicant is Depuy, Inc., and the statement places this activity at the DePuy (Ireland) and Paragon Medical, Inc facilities.

The identifier links this filing to the existing P830055 approval as a supplement rather than an original PMA. The notice describes supply and process scope only; it does not establish safety, clinical effectiveness or any new indication, and the source statement does not specify which individual components use the added supplier, the quantity of powder involved or any verification or validation detail.

The product category listed is a semi-constrained, metal/polymer, mobile-bearing patellofemoral tibial knee prosthesis under product code NJL, specialty Orthopedic.

FDA approval order statement

an addition of ingos sub-tier supplier for a supplier providing titanium powder for the 3D printing processes for some ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System components at the DePuy (Ireland) and Paragon Medical, Inc facilities
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P830055/S372
Regulatory pathway
PMA supplement
Applicant
Depuy, Inc.
Product code
NJL
Decision code
OK30
Decision date
Sep 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.

Applicant
Depuy, Inc.
Product code
NJL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830055/S372 received

    Application receipt date recorded by FDA.

  2. P830055/S374 · Related supplement

    LCS(R) TOTAL KNEE SYSTEM, specifically ATTUNE Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral C

  3. P830055/S372 · FDA decision

    30-Day Notice

  4. P830055/S376 · Related supplement

    Attune Rotating Platform (RP) Total Knee System and the DePuy P.F.C. Sigma Rotating Platform (RP) Total Knee System an

  5. P830055/S351 · Related supplement

    Attune Revision Knee System

  6. P830055/S377 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Revision Rotating Platform (RP) Total Knee System, and M.B.T. Re

  7. P830055/S379 · Related supplement

    ATTUNE Revision Knee System

  8. P830055/S381 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System

Timeline entries are records held by MedtechLedger for P830055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830055

Explore the linked device profile

Other records with product code NJL

Product / regulatory recordCompanyPathwayDecision dateSource
Zimmer, Inc.PMA supplementOct 16, 2026FDA
Zimmer, Inc.PMA supplementSep 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
P.O. Box 988, 700 Orthopaedic Dr., Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records